SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

Original reporting
Published Nov 16, 2026, 7:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too — source image
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

Each firm has a distinct regulatory or partnership catalyst that could drive short‑term price moves.

02

Market read

Fresh FDA‑related news and high‑profile partnerships provide actionable trading ideas in the oncology biotech space.

03

What to watch

Potential competition from other AML and bladder cancer therapies could limit upside.

Relevance 8/10Novelty 8/10Timing: immediate today

Background

The article aggregates recent developments for several cancer‑focused biotech firms that appeared on BlackRock and Vanguard buy lists.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas Therapeutics disclosed timing of its Phase 3 Regal trial and potential FDA approval for its AML immunotherapy GPS, a fresh catalyst for the stock.

Expected impact

likely upward pressure as investors price in potential approval

Evidence & confidence

Phase 3 trial reaching final analysis is a material event for a biotech, often driving share gains.

$IBRXBullishHigh confidence
Context

ImmunityBio reported improved response rates when adding its bladder cancer drug Anktiva to BCG and plans to seek expanded FDA approval by year‑end.

Expected impact

likely upward pressure as market anticipates regulatory clearance

Evidence & confidence

Positive early data and a clear regulatory path are strong upside drivers for a small‑cap biotech.

$IOVABullishHigh confidence
Context

Iovance highlighted its Amtagvi sales surge and a Phase 3 trial combining Amtagvi with Merck's Keytruda for advanced melanoma, adding a high‑profile partnership.

Expected impact

likely upward pressure as investors value the Merck collaboration

Evidence & confidence

Collaboration with a major pharma and robust sales growth are positive signals for the company's outlook.

Market effects

Positive FDA progress may lift broader oncology biotech sector.

US biotech market sees fresh catalyst, supporting sector momentum.

Regulatory approvals in oncology have worldwide relevance for cancer therapy pipelines.

Counterpoint

If trial data later disappoints, stocks could face sharp reversals.

Key entities

  • Sellas Therapeutics

    Biotech developing AML immunotherapy GPS.

  • ImmunityBio

    Biotech advancing bladder cancer therapy Anktiva.

  • Iovance Biotherapeutics

    Cell‑therapy developer partnering with Merck on melanoma.

Related articles

$PFEMed

EU Backs Earlier-Line Moves in Prostate and Kidney Cancer

The European Medicines Agency's CHMP recommended new indications for Pfizer's Talzenna and Merck's Welireg. Talzenna, for prostate cancer, and Welireg, for kidney cancer, could move earlier in treatment if approved by the European Commission. Both drugs showed improved outcomes in clinical trials, with Talzenna reducing progression risk by 52% and Welireg improving progression-free survival.

$MRKMedAI 8/10

Merck KGaA, Darmstadt, Germany Signs Definitive Agreement to Acquire Rapid Micro Biosystems, Advancing Automation in Pharmaceutical Quality Control

Merck KGaA (Germany) agreed to acquire Rapid Micro Biosystems (Nasdaq: RPID) for $0.75 per share. The deal aims to enhance Merck's quality-control workflows with Rapid Micro's automated microbial testing platform, Growth Direct. The acquisition is expected to close in December 2026, subject to regulatory approvals and shareholder tender.